Global Impact Fund

The Global Health Investment Fund (GHIF) is a social impact venture capital fund focused on the development of drugs, vaccines, and diagnostics for neglected diseases that disproportionately affect low-income populations. Launched in 2013 by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation, the fund provides late-stage financing to accelerate the commercialization of transformative global health technologies. GHIF's portfolio includes companies working on infectious diseases such as tuberculosis and malaria, as well as maternal and child health solutions. By leveraging a unique partial guarantee from the Gates Foundation and the Swedish International Development Cooperation Agency, the fund attracts private capital to high-impact R&D projects. Notable successes include funding the development of moxidectin for river blindness through Medicines Development for Global Health.